EQS-News: Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
Error message
- Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
- Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
- Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
EQS-News: Formycon AG / Key word(s): Regulatory Admission Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept) 27.11.2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release // November 27, 2023
Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept) Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Klinge Biopharma GmbH (Klinge) announce that the marketing authorization application (MAA) for FYB203, a biosimilar candidate for Eylea®1 (Active ingredient: Aflibercept) has been submitted to the European Medicines Agency (EMA). Eylea® is used in the treatment of neovascular age-related macular degeneration (nAMD) and other severe retinal diseases. It inhibits the vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina. In the first nine months of 2023, Eylea reached global sales of around US$ 7 billion[[i]], underlining its status as the currently best-selling drug in the field of anti-VEGF therapies. "Our latest MAA submission once again demonstrates the high performance and reliability of the entire #TeamFormycon. We are very pleased that with FYB203 we have filed our second biosimilar candidate in the ophthalmology space that is likely to become even more important in the coming years in light of the aging population.”, says Formycon CEO Dr. Stefan Glombitza. 1 Eylea® is a registered Trademark of Regeneron Pharmaceuticals Inc.
About Formycon: About Biosimilars: Contact: Disclaimer:
[i] https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-third-quarter-2023-financial-and-operating
27.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Formycon AG |
Fraunhoferstraße 15 | |
82152 Planegg-Martinsried | |
Germany | |
Phone: | 089 864667 100 |
Fax: | 089 864667 110 |
Internet: | www.formycon.com |
ISIN: | DE000A1EWVY8 |
WKN: | A1EWVY |
Indices: | Scale 30 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1781883 |
End of News | EQS News Service |
|
1781883 27.11.2023 CET/CEST